Quisel John D sold $2.6M of IRON
Quisel John D (Chief Executive Officer) sold 33,000 shares of Disc Medicine, Inc. (IRON) at an average of $79.15 ($78.11–$79.84, $2.61M total) across 3 trades on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor insider activity as a sentiment input, but 10b5-1 plans generally make the information less predictive of near-term fundamentals.
Market read
New Form 4 details show a $2.61M CEO sale at ~$78.11 to $79.84 per share on Aug. 17, filed Aug. 18.
What to watch
The article does not state motivations, tax needs, or whether other insiders sold/bought around the same time, limiting inference from a single transaction.
Background
The article is an SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON) by CEO John D. Quisel.
Ticker impact
Disc Medicine CEO Quisel sold about 33,000 shares in open-market trades totaling $2.61M, disclosed via Form 4 filed Aug. 18.
Likely limited near-term impact; any reaction is more about sentiment than fundamentals.
Form 4 provides fresh transaction details (size, dates, prices) and confirms a 10b5-1 plan, which often indicates routine, scheduled selling rather than new negative information.
Market effects
Minimal sector read-through; this is an issuer-specific insider transaction without disclosed operational or regulatory changes.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerIRON
Disc Medicine, Inc., the company whose CEO insider sale is disclosed.
- insiderQuisel John D
CEO and director of Disc Medicine, Inc., reported open-market sales under a 10b5-1 plan.